Houston-based Avance Biosciences' new Next-Generation Sequencing Center of Excellence will pursue breakthroughs in biologics, cell therapy and gene therapy. Photo via Getty Images.

Houston-based Avance Biosciences has launched the Next-Generation Sequencing Center of Excellence, designed to enhance the company’s sequencing capabilities for drug development. Specifically, the facility at the company’s main campus in Northwest Houston will pursue breakthroughs in biologics, cell therapy and gene therapy.

In the drug industry, sequencing refers to studying nucleotides in DNA and RNA molecules. Nucleotides are the building blocks of DNA and RNA.

“This is a major milestone for Avance Biosciences as we continue to support the evolving needs of biologics and cell and gene therapy developers,” Xuening “James” Huang, co-founder, CEO and chief technology officer of Avance, said in a news release. “By consolidating state-of-the-art sequencing platforms and scientific talent, we’ve created a highly capable organization ready to solve complex genomic challenges with precision and compliance.”

In 2013, Avance rolled out next-generation sequencing (NGS) that complies with federal guidelines. Since then, Avance “has remained at the forefront of regulated sequencing services,” the company said. “The launch of the (new center) strengthens the company’s ability to deliver accurate, reproducible, and regulatory-aligned sequencing data across a wide array of therapeutic modalities.”

Cal Froberg, senior vice president of sales and marketing at Avance, said pharmaceutical and biotech clients trust the company’s technical capabilities and regulatory compliance.

“With the ever-changing global landscape and increasing scrutiny around international sample shipments, conducting advanced, cost-effective NGS testing domestically is now more feasible than ever,” Froberg said. “Our clients have confidence that their samples will remain in the U.S.”

Avance, founded in 2010, plans to hold an open house at the new facility in September to showcase its capabilities, technology, talent, and services. The company’s services include sequencing, molecular biology, cell-based testing, and bioanalytical testing.
Baylor College of Medicine, Texas A&M and University of Houston researchers have designed SPACe, a new open-source image analysis platform. Photo via Getty Images

Texas universities develop innovative open-source platform for cell analysis

picture this

What do labs do when faced with large amounts of imaging data? Powerful cloud computing systems have long been the answer to that question, but a new riposte comes from SPACe.

That’s the name of a new open-source image analysis platform designed by researchers at Baylor College of Medicine, Texas A&M University and the University of Houston.

SPACe, or Swift Phenotypic Analysis of Cells, was created to be used on standard computers that even small labs can access, meaning cellular analysis using images produced through cell painting has a lower barrier to entry than ever before.

“The pharmaceutical industry has been accustomed to simplifying complex data into single metrics. This platform allows us to shift away from that approach and instead capture the full diversity of cellular responses, providing richer, more informative data that can reveal new avenues for drug development,” Michael Mancini, professor of molecular and cellular biology and director of the Gulf Coast Consortium Center for Advanced Microscopy and Image Informatics co-located at Baylor College of Medicine and TAMU Institute for Bioscience and Technology.

SPACe is not only accessible because of its less substantial computational needs. Because the platform is open-source, it’s available to anyone who needs it. And it can be used by academic and pharmaceutical researchers alike.

“The platform allows for the identification of non-toxic effects of drugs, such as alterations in cell shape or effects on specific organelles, which are often overlooked by traditional assays that focus largely on cell viability,” says Fabio Stossi, currently a senior scientist with St. Jude Children’s Research Hospital, the lead author who was at Baylor during the development of SPACe.

The platform is a better means than ever of analyzing thousands of individual cells through automated imaging platforms, thereby better capturing the variability of biological processes. Through that, SPACe allows scientists an enhanced understanding of the interactions between drugs and cells, and does it on standard computers, translating to scientists performing large-scale drug screenings with greater ease.

"This tool could be a game-changer in how we understand cellular biology and discover new drugs. By capturing the full complexity of cellular responses, we are opening new doors for drug discovery that go beyond toxicity,” says Stossi.

And the fact that it’s open-source allows scientists to access SPACe for free right now. Researchers interested in using the platform can access it through Github at github.com/dlabate/SPACe. This early version could already make waves in research, but the team also plans to continually improve their product with the help of collaborations with other institutions.

Texas Medical Center Innovation won a Prix Galien Award, which has been described as being comparable to the Nobel Prize for the life science community. Photo by Natalie Harms/InnovationMap

Houston's Texas Medical Center wins prestigious global award recognizing leaders in life science innovation

new bling

Last month, a global organization honored innovation leaders in life sciences, and the Texas Medical Center was among the recipients of the prestigious awards program.

The 18th annual Prix Galien Awards Gala awarded TMC Innovation with the win in the "Incubators, Accelerators and Equity" category. The Galien Foundation created the awards program in 1970 in honor of Galien, the father of medical science and modern pharmacology. Alongside TMC, the other winners represented biotech, digital health, startups, and more.

"We are super proud of this distinction," Tom Luby, director of TMC Innovation says at Envision 2024 last month, crediting the TMCi team and TMC leadership for the award. "We lean on a lot of advisers and experts — people who volunteer their time to work with startups. Without (them), we would not have been successful."

Luby explains that a Prix Galien Award holds a Nobel Prize level of significance for the community.

TMCi was named a finalist in August, and competed against programs from Cedars-Sinai, Mayo Foundation for Medical Education and Research, TechConnect, and more.

"The Awards Committee is honored to witness the exceptional dedication and creativity of our nominees as they turn visionary ideas into transformative solutions for patients worldwide," says Michael Rosenblatt, chair of the Prix Galien USA Awards Committee, in a news release. "Their unwavering commitment to advancing patient care is truly commendable, and we are honored to celebrate their outstanding contributions to global health."

The award is displayed at TMC Innovation's office, located in the medical center at 2450 Holcombe Blvd.

Nádia Skorupa Parachin joined Cemvita as vice president of industrial biotechnology. Photo courtesy of Cemvita

Houston biotech company expands leadership as it commercializes sustainable products

joining the team

Houston-based biotech company Cemvita recently tapped two executives to help commercialize its sustainable fuel made from carbon waste.

Nádia Skorupa Parachin came aboard as vice president of industrial biotechnology, and Phil Garcia was promoted to vice president of commercialization.

Parachin most recently oversaw several projects at Boston-based biotech company Ginkjo Bioworks. She previously co-founded Brazilian biotech startup Integra Bioprocessos.

Parachin will lead the Cemvita team that’s developing technology for production of bio-manufactured oil.

“It’s a fantastic moment, as we’re poised to take our prototyping to the next level, and all under the innovative direction of our co-founder Tara Karimi,” Parachin says in a news release. “We will be bringing something truly remarkable to market and ensuring it’s cost-effective.”

Moji Karimi, co-founder and CEO of Cemvita, says the hiring of Parachin represents “the natural next step” toward commercializing the startup’s carbon-to-oil process.

“Her background prepared her to bring the best out of the scientists at the inflection point of commercialization — really bringing things to life,” says Moji Karimi, Tara’s brother.

Parachin joins Garcia on Cemvita’s executive team.

Before being promoted to vice president of commercialization, Garcia was the startup’s commercial director and business development manager. He has a background in engineering and business development.

Founded in 2017, Cemvita recently announced a breakthrough that enables production of large quantities of oil derived from carbon waste.

In 2023, United Airlines agreed to buy up to one billion gallons of sustainable aviation fuel from Cemvita’s first full-scale plant over the course of 20 years.

Cemvita’s investors include the UAV Sustainable Flight Fund, an investment arm of Chicago-based United; Oxy Low Carbon Ventures, an investment arm of Houston-based energy company Occidental Petroleum; and Japanese equipment and machinery manufacturer Mitsubishi Heavy Industries.

------

This article originally ran on EnergyCapital.

Biostate AI has emerged from stealth this week — with $4 million and a mission to design AI products to predict human and animal health changes. Photo via Getty Images

New health-focused generative AI company emerges from stealth with Houston office, $4M in funding

eyes on ai

A new scalable biodata foundry startup has emerged from stealth with $4 million in investment funding and two new health care artificial intelligence tools. The company is co-located in Houston and Palo Alto, California.

Biostate AI was co-founded by former Rice Professor David Zhang, who serves as the company's CEO, in 2023. With the launch, the company announced two service products: Total RNA sequencing and Copilot for RNAseq data analysis, Biostate reveals in a press release.

"The successful training of any AI well requires large quantities of relevant and high-quality data," Zhang says in the release. "Biostate AI has developed the instrumental technologies to facilitate the collection of more biological data at lower costs. We are pleased to offer these capabilities to academic and industry partners and collaborators."

The company has raised more than $4 million in venture funding. Matter Venture Partners led the initial round, with participation from Vision Plus Capital, Catapult VC, and the California Institute of Technology through the Caltech Seed Fund. Additional investors included Dario Amodei, CEO of Anthropic; Joris Poort, CEO of Rescale; Michael Schnall-Levin, CTO of 10X Genomics; and Emily Leproust, CEO of Twist Bioscience.

"AI is the next frontier and AI needs data, and biological data is a lot harder to get than text or images. We are excited about the potential for Biostate's technology to dramatically lower the cost of collecting RNAseq datasets," adds Haomiao Huang, founding partner at Matter Venture Partners, in the release. "As a US company, Biostate's affordable AI-embedded CRO services are much needed today as the supply of preclinical research services shrinks due to geopolitical tensions."

With an ultimate goal of designing AI products to predict human and animal health changes, Biostate AI is looking to partner with academic researchers, hospital biorepositories, and pharma and other biotech companies.

In addition to its two launched products, Biostate AI has filed nine pending patents on its technologies and is collaborating with Twist Bioscience and California Institute of Technology.

With its official launch, Biostate AI also debut OmicsWeb Copilot, a conversational AI that aids biologists in and visualizing data. Using large-language models, the platform provides access to over 1000 unique RNAseq datasets collected by the Biostate team.

"Bioinformatic analysis of RNAseq and other omics data is a highly complex, multi-step process that currently takes many hours of dedicated specialized programming," explains Ashwin Gopinath, co-founder and CTO of Biostate AI, in the release. "As we scaled up our RNAseq data collection in the past year, we started building OmicsWeb Copilot as an internal tool to help our scientists make sense of the data. And then we realized other people may also find this tool useful, so we're opening it up to the general public for free."

Biostate is asking those interested in collaboration to reach out at partnerships@biostate.ai.

San Jacinto College's new Center for Biotechnology at the Generation Park Campus is expected to be completed early next year. Photo courtesy of San Jacinto College

Houston-area college breaks ground on new biotechnology program, launches curriculum

coming soon

San Jacinto College and McCord Development Inc. broke ground on the new Center for Biotechnology at the Generation Park Campus in Northeast Houston.

The 4,000-square-foot, state-of-the-art facility is slated to allow for more hands-on training within simulated environments and will allow students to earn associate of applied science degrees in biomanufacturing technology, as well as credentials for those already in the workforce. It's scheduled to be completed in the first quarter of 2025.

“The Center and the overall components of the Biotechnology program will play a vital role in meeting the growing demand for skilled professionals in the biotechnology sector,” Brenda Hellyer, chancellor of San Jacinto College, says in a statement.

“We are committed to equipping our students with the skills and knowledge necessary for success in the dynamic biopharmaceutical industry," she continues. "Our vision is to not only meet the workforce needs of today but will also shape the future of biotechnology education and training in our region.”

San Jacinto College and McCord Development Inc. celebrated the groundbreaking of the new Center for Biotechnology at the Generation Park Campus in Northeast Houston. Photo courtesy of San Jacinto College

The new Center for Biotechnology curriculum is in partnership with the Ireland-based National Institute for Bioprocessing Research and Training. It is the only NIBRT-licensed training in the Southwest and Southeast region.

At the groundbreaking, San Jacinto College celebrated the ribbon-cutting for the Biomanufacturing Training Program at the South Campus, the first of the college's comprehensive biotechnology offerings.

The Biomanufacturing Training Program will be a customizable two-week hybrid program that combines theoretical teachings with hands-on experience.

“This program is designed to provide a seamless entry into the field for new professionals, with a focus on practical experience and exposure to industry practices,” Christopher Wild, executive director of San Jacinto College Center for Biotechnology, added in a statement.

The new center is part of Generation Park, a 4,300-acre master-planned development in Northeast Houston. In late 2022, San Jac and McCord, which is developing Generation Park, shared that they had signed a memorandum of understanding with the NIBRT to launch the program and center.

At the time, San Jacinto College was slated to be the institute’s sixth global partner and second U.S. partner.

Last summer, McCord also revealed plans for its 45-acre biomanufacturing campus at Generation Park.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston company wins AHA competition for pediatric heart valve design

winner, winner

Houston-based PolyVascular, which develops minimally invasive solutions for children with congenital heart disease, was named the overall winner of the American Heart Association’s annual Health Tech Competition earlier this month.

The company was founded in 2014 by Dr. Henri Justino and Daniel Harrington and was part of TMCi's 2017 medical device cohort. It is developing the first polymer-based transcatheter pulmonary valve designed specifically for young children, allowing for precise sizing and redilation as the child grows while also avoiding degradation. PolyVascular has completed preclinical studies and is working toward regulatory submissions, an early feasibility study and its first-in-human clinical trial thanks to a recent SBIR grant from the National Heart, Lung, and Blood Institute.

With the new AHA honor, PolyVascular will be invited to join the association’s Center for Health Technology & Innovation Innovators’ Network, which connects entrepreneurs, providers and researchers to share and advance innovation in cardiovascular and brain health.

“This is a tremendous honor for PolyVascular—we’re especially proud to bring hope to families and children living with congenital heart defects,” Justino said in a news release. “Our technology—a minimally invasive valve that can be expanded over time to grow with the child—has the potential to dramatically reduce the need for repeated open-heart surgeries.”

The Health Tech Competition is a live forum for health care innovators to present their digital solutions for treating or preventing cardiovascular diseases and stroke.

Finalists from around the world addressed heart failure, hypertension, congenital heart defects and other issues that exist in cardiovascular, brain and metabolic health. Solutions were evaluated on the criteria of validity, scientific rigor and impact.

The judges included Texas-based Dr. Eric D. Peterson, professor of medicine in the division of cardiology at UT Southwestern Medical Center, and Dr. Asif Ali, clinical associate professor of cardiovascular medicine at the University of Texas Medical School in Houston and director at Cena Research Institute.

According to the American Heart Association, nearly half of U.S. adults live with some form of cardiovascular disease or stroke.

“The American Heart Association plays a pivotal role in advancing innovative care pathways, and we’re excited that our solution aligns with its guidelines and mission,” Justino said in a news release. “It’s time these life-changing technologies reach the youngest patients, just as they already do for adults.”

EO Houston is where ambitious founders go to scale smarter

Don't Go It Alone

Scaling a business from early traction into true growth is one of the most exciting — and punishing — chapters of entrepreneurship. Houston founders know this better than most. Our city is built on ambition: fast-moving industries, talent from around the world, and opportunities that expand as large as the Texas sky.

But as many entrepreneurs eventually learn, scaling isn’t simply “more of what worked.” It requires new systems, new thinking, and often, a new version of the founder. Even the most capable founders eventually face decisions, pressures, and turning points that only other entrepreneurs can truly understand.

Entrepreneurs’ Organization, a global peer-to-peer network of more than 18,000 business owners across 220 chapters in 75+ countries, exists for exactly this stage. One of the largest chapters in the organization, EO Houston brings that global community to life locally, offering founders the connection, learning, and accountability needed to grow sustainably and to grow up as leaders.

A community where founders learn at the highest level
The real value of EO emerges in the lived experiences of other entrepreneurs. When Houston-area founders talk about the moments growth nearly broke their companies, a universal theme appears: you can’t do it alone.

EO Houston member Robert De Los Santos of Sky High Party Rentals learned this the hard way when rapid post-COVID growth made expansion feel limitless — until it wasn’t.

“After COVID, we doubled every year and assumed inventory was the limit. In 2023 we overbought, only to realize demand had peaked. That taught us a hard truth: growth in one city has ceilings. Expanding into Austin and Dallas — the Texas Triangle — gave us new markets to put our inventory to work while we figured out how to penetrate Houston better. The challenge shifted from a strategy of ‘buy more units for demand’ to learning how to tackle the challenges of ‘leading across cities.’”

Founders often enter EO exhausted from trying to maintain control as things grow more complex. Many discover, like Jarred King of Summit Firms, that scaling requires the difficult shift from doing everything to building the team that can.

“We grew quickly because of my network, relationships, and hustle… but I was doing all the work,” King says. “I realized at that point you have to delegate — not just busy work, but important decisions to your key team, as well as set up really effective SOPs.”

“The uncomfortable truth is that you are no longer the best person for most jobs in your company," agrees Darren Randle of Houston Tents & Events. "Your inability to delegate or hire people smarter than you in key leadership and management level roles will become the single biggest drag on the entire business. You have to accept that your original 'hustle' is now a scalability risk."

Making hard decisions, such as walking away from customers or contracts, can feel like less of a sting when you know others have also been faced with tough choices. Aaron Gillaspie of West U's My Salon Suite recalls, “You can’t be everything to everyone, it’s ok to say no, and just understand some customers aren’t the right fit. It’s a two way street and both must win.”

Perspective is perhaps the most important reality check that members find at EO.

“Bigger volume will not make problems go away — you just got to get used to walking the tightrope," says Roger Pombrol of Emerald Standard. "Develop a system for good balance and do not freak out. Scared is no way to live your life. It’s ok if you fall. Your family will still love you. Money is just money. Love is love. The world tries to make you conflate them, but don’t."

Actionable insights from entrepreneurs who’ve already scaled
Conversations like these are happening every month inside EO Forum Meeting. Each EO chapter is divided into several small Forums. These confidential, committed group of 7–10 entrepreneurs who meet to share the real five percent of what they’re experiencing. It’s not advice, but experience — shared candidly, respectfully, and with the kind of vulnerability that leads to breakthroughs.

What makes Forum so impactful is the honesty it draws out. Entrepreneurs are often surrounded by employees, partners, and even family members who rely on them for answers, but seldom do they have a group where vulnerability is not only welcomed, but expected.

Learning experiences that match your ambition
EO supports that growth far beyond peer groups. Through the organization’s global partnerships with institutions like Harvard, Oxford, and INSEAD, Houston members gain access to executive-level learning experiences designed specifically for entrepreneurs.

These programs help founders step out of the day-to-day and think strategically about competitive advantage, innovation, and organizational leadership. Paired with ongoing learning through EO Jumpstart, Nano Learning, and its global library of member-created content, founders stay informed, challenged, and ahead of emerging trends.

And through global communities — ranging from EO Women and EO Under 35 to industry-specific groups — Houston members tap into expertise that spans continents and sectors. Whether someone is navigating M&A, exploring international expansion, or integrating new technologies, the right perspectives are always within reach.

What truly distinguishes EO Houston, however, is its culture. Houston’s entrepreneurial landscape is uniquely diverse and resilient, filled with founders who are hungry to build, innovate, and elevate the city’s business community. EO Houston amplifies that spirit, creating relationships that are as supportive as they are strategic. Many members describe the chapter not simply as a network, but as a catalyst for becoming better leaders, better thinkers, and — just as importantly — better human beings.

Your next level starts here
For entrepreneurs who are ready to scale—beyond their first million, beyond their current comfort zone, and toward a future that requires sharper leadership and stronger community—EO Houston offers an unmatched platform. It is a place where ambitious founders grow faster, think bigger, and gain the confidence to take bold next steps.

If you’re ready to elevate your business and your leadership alongside people who understand the journey, EO Houston is ready to welcome you. Your next level starts with the peers who can help you reach it. Learn more and become a member here.

3 Houston companies land on Deloitte’s Technology Fast 500 list

trending up

Three Houston companies have made this year’s Deloitte North America Technology Fast 500 list.

The report ranks the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. The Houston companies to make the list, along with their revenue growth rates from 2021-2024, include:

  • No. 16 Action1 Corp., a provider of cybersecurity software. Growth rate: 7,265 percent
  • No. 92 Cart.com, a commerce and logistics platform. Growth rate: 1,053 percent
  • No. 312 Tellihealth, a remote health care platform. Growth rate: 244 percent

“Houston’s unique blend of entrepreneurial energy and innovation continues to strengthen the local business community, and I’m thrilled to see Houston companies honored on the 2025 Deloitte Technology Fast 500 list. Congratulations to all the winners,” said Melinda Yee, managing partner in Deloitte’s Houston office.

Action1 is no stranger to lists like the Deloitte Technology Fast 500. For instance, the company ranked first among software companies and 29th overall on this year’s Inc. 5000, a list of the country’s fastest-growing private companies. Its growth rate from 2021 to 2024 reached 7,188 percent.

Mike Walters, president and co-founder of Action1, said in August that the Inc. 5000 achievement “reflects the dedication of Action1’s global team, who continue to execute against an ambitious vision: a world where cyberattacks exploiting vulnerabilities are entirely prevented across all types of devices, operating systems, and applications.”

Atlanta-based Impericus, operator of an AI-powered platform that connects health care providers with pharmaceutical and life sciences companies, topped the Deloitte list with a 2021-24 growth rate of 29,738 percent.

“Our mission is to set the standard for ethical AI-powered physician connections to pharma resources, accelerating and expanding patient access to needed treatments,” said Dr. Osama Hashmi, a dermatologist who’s co-founder and CEO of Impiricus. “As we continue to innovate quickly, we remain committed to building ethical bridges across this vital ecosystem.”